159,271 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 159,271 shares of the medical research company's stock, valued at approximately $8,949,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Exact Sciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in EXAS. Thompson Investment Management Inc. raised its stake in Exact Sciences by 17.8% during the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock valued at $13,585,000 after acquiring an additional 36,505 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Exact Sciences by 32.2% during the fourth quarter. Jones Financial Companies Lllp now owns 9,508 shares of the medical research company's stock valued at $534,000 after purchasing an additional 2,315 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Exact Sciences during the fourth quarter valued at about $478,000. Sanctuary Advisors LLC lifted its holdings in Exact Sciences by 2.0% in the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company's stock worth $763,000 after purchasing an additional 269 shares during the period. Finally, Robeco Institutional Asset Management B.V. grew its position in Exact Sciences by 37.5% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 37,286 shares of the medical research company's stock valued at $2,095,000 after buying an additional 10,165 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Down 2.3%

Shares of EXAS traded down $1.29 during mid-day trading on Tuesday, hitting $54.84. 3,417,735 shares of the company's stock were exchanged, compared to its average volume of 2,594,106. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a twelve month low of $39.97 and a twelve month high of $72.83. The firm has a fifty day moving average of $48.95 and a two-hundred day moving average of $52.09. The stock has a market cap of $10.34 billion, a price-to-earnings ratio of -9.85 and a beta of 0.92.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $706.79 million for the quarter, compared to the consensus estimate of $688.58 million. During the same period in the prior year, the business posted ($0.60) earnings per share. The business's quarterly revenue was up 10.9% on a year-over-year basis. On average, sell-side analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

EXAS has been the topic of a number of recent analyst reports. Guggenheim restated a "buy" rating and set a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. Bank of America lowered their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th. Royal Bank of Canada upped their target price on Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Mizuho began coverage on shares of Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 target price on the stock. Finally, Robert W. Baird raised their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $70.90.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.